MedPath

Effect of Individual Cognitive Stimulation on Memory and Executive Function in Older Adults With Alzheimer's Disease

Not Applicable
Completed
Conditions
Neurocognitive Disorders
Cognitive Decline
Dementia
Cognitive Impairment
Cognitive Dysfunction
Interventions
Behavioral: Cognitive stimulation
Registration Number
NCT05433493
Lead Sponsor
Rsocialform - Geriatria, Lda
Brief Summary

This multicentre study, with a randomised controlled repeated measures experimental design, will be conducted in several Portuguese institutions, which provide care and supportive services for older adults diagnosed with mild or moderate Alzheimer's disease (AD), with an aim to assess the effect of individual cognitive stimulation (CS) on memory and executive functioning. Participants in the intervention group will attend 24 individual CS sessions, twice weekly for 12 weeks. Participants in the control group will complete their usual routines without any activity restrictions.

Detailed Description

Neurocognitive disorders (NCD) currently affect around 55 million people worldwide and expected to increase to 78 million by 2030 and 139 million by 2050, with Alzheimer's disease (AD) potentially accounting for 60-70% of dementia cases. Dementia is a syndrome, generally chronic or progressive in nature, that causes deterioration of cognitive function, particularly memory and executive functions, beyond what is expected in normal aging. However, there is evidence that in the early stages of NCD, people can learn and improve their cognitive functions through interventions such as CS. CS is a psychosocial intervention and a non-pharmacological therapy recommended by international practice guidelines for people with mild-to-moderate stage AD. However, it is also important to investigate whether NCD generates new skills or only preserves acquired skills, given that AD manifests initially and notably with deficits in memory and learning, sometimes accompanied by deficits in executive functions. Testing the effectiveness of CS by recruiting a representative sample from several Portuguese districts and using a CS programme with detailed and comprehendible content, may elicit relevant evidence in clinical practice, contribute to the development of social development programs and initiatives to ensure social protection and inclusion, promote recurrent therapeutic interventions in Portuguese institutions with provide care and supporting services for older adults with dementia, and strengthen research on non-pharmacological therapies. Thus, this multicentre, randomised controlled study is essential to analyse the effects of the individual CS on global cognitive function and specific cognitive domains (e.g., executive functioning, memory) in older adults with mild or moderate AD.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
142
Inclusion Criteria
  • Age 65 or over.
  • Receive care and support services for older adults for at least three months.
  • Alzheimer's disease, according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, 5th edition.
  • Ability to communicate and understand.
  • Native speakers of Portuguese.
  • To have given informed consent for the project, duly completed and signed, after previous information.
  • Total scores between 10 and 24 points on the Mini Mental State Examination.
Exclusion Criteria
  • Cannot read and write.
  • Severe sensory and physical limitations and/or an acute or serious illness preventing participation in the CS sessions.
  • Evidence of aggressive and disruptive behaviour, as indicated by the reference technicians of the institution to which the participant is linked.
  • Consumption of psychoactive substances, taking neuroleptics and/or antipsychotics in the last two months.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Intervention groupCognitive stimulationParticipants who meet the inclusion criteria will be randomly assigned to the intervention group receiving individual CS or to the control group receiving treatment as usual (participating in the activities previously established in their individual intervention plan). Participants in the intervention group will participate in two individual CS sessions per week for 12 weeks in addition to their treatment as usual. The sessions will include the same protocol in every participant site.
Primary Outcome Measures
NameTimeMethod
Memory function evaluated through Free and Cued Selective Reminding Test (FCSRT)baseline

FCSRT is a verbal learning and memory test that allows prompting the encoding and retrieval conditions by using semantic cues on learning and recall trials. It is composed of 16 semantically categorised, unrelated items/words.

Cognitive functioning assessed through Mini-Mental State Examination (MMSE)baseline

Cognitive functioning assessed by the Mini-Mental State Examination (MMSE), a gold standard screening tool for assessing global cognitive function. Scores range from 0 to 30, with higher scores indicating better cognitive functioning.

Cognitive functioning assessed through Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-COG)baseline

Evaluates the severity of cognitive deficits in AD in the following domains: memory, orientation, language, praxis and constructive capacity. The total score in the Portuguese version of ADAS-Cog is composed of 11 subtests in the cognitive part and varies between 0 (better performance) and 68 points (worse performance), i.e., higher scores equals better performance.

Memory function evaluated through Memory Alteration Test (MAT)baseline

The MAT is used to assess memory function. It is an easy and quick instrument that assesses five memory domains: temporal orientation, encoding, semantic memory, free recall, and cued recall. Total scores range from 0 to 50, with higher scores indicating better memory. It has good psychometric properties and is highly sensitive to mild cognitive decline.

Change in memory function evaluated through Memory Alteration Test (MAT)12 weeks after end of intervention

The MAT is used to assess memory function. It is an easy and quick instrument that assesses five memory domains: temporal orientation, encoding, semantic memory, free recall, and cued recall. Total scores range from 0 to 50, with higher scores indicating better memory. It has good psychometric properties and is highly sensitive to mild cognitive decline.

Change in memory function evaluated through Free and Cued Selective Reminding Test (FCSRT)12 weeks after end of intervention

FCSRT is a verbal learning and memory test that allows prompting the encoding and retrieval conditions by using semantic cues on learning and recall trials. It is composed of 16 semantically categorised, unrelated items/words.

Change in cognitive functioning assessed through Mini-Mental State Examination (MMSE)12 weeks after end of intervention

Change in cognitive functioning evaluated by the Mini-Mental State Examination (MMSE), a gold standard screening tool for assessing global cognitive function.

Scores range from 0 to 30, with higher scores indicating better cognitive functioning.

Executive functions assessed through Frontal Assessment Battery (FAB)baseline

FAB assesses executive functions such as abstract thinking, mental flexibility, motor programming, interference sensibility, inhibitory control and environmental independence. Scores range between 0 - 18 points with higher scores indicating better cognitive function.

Change in executive functions assessed through Trail Making Test (TMT)12 weeks after end of intervention

TMT is one of the most widely used instruments in clinical and experimental neuropsychology. It is very sensitive to identify cognitive impairments, measuring simple motor and spatial skills, basic sequencing skills, mental flexibility, selective attention, visuo-perceptual skills, motor speed, and executive functions. Higher scores indicate greater impairment.

Change in cognitive functioning assessed through Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-COG)12 weeks after end of intervention

Evaluates the severity of cognitive deficits in AD in the following domains: memory, orientation, language, praxis and constructive capacity. The total score in the Portuguese version of ADAS-Cog is composed of 11 subtests in the cognitive part and varies between 0 (better performance) and 68 points (worse performance), i.e., higher scores equals better performance.

Change in executive functions assessed through Frontal Assessment Battery (FAB)12 weeks after end of intervention

FAB assesses executive functions such as abstract thinking, mental flexibility, motor programming, interference sensibility, inhibitory control and environmental independence. Scores range between 0 - 18 points with higher scores indicating better cognitive function.

Executive functions assessed through Trail Making Test (TMT)baseline

TMT is one of the most widely used instruments in clinical and experimental neuropsychology. It is very sensitive to identify cognitive impairments, measuring simple motor and spatial skills, basic sequencing skills, mental flexibility, selective attention, visuo-perceptual skills, motor speed, and executive functions. Higher scores indicate greater impairment.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (14)

Cediara - Associação de Solidariedade Social de Ribeira de Fráguas

🇵🇹

Aveiro, Portugal

Centro Social e Cultural S. Pedro de Bairro

🇵🇹

Braga, Portugal

Rsocialform - Geriatria, Lda

🇵🇹

Mealhada, Aveiro, Portugal

Centro Social Vale do Homem - Casa da Alegria

🇵🇹

Braga, Portugal

Santa Casa da Misericórdia de Castro Marim

🇵🇹

Faro, Portugal

Associação de Socorros da Freguesia de Turcifal

🇵🇹

Lisboa, Portugal

Centro de Apoio Social de Oeiras - IASFA

🇵🇹

Lisboa, Portugal

Associação de Apoio Social de Perafita

🇵🇹

Porto, Portugal

Santa Casa da Misericórdia de Coruche

🇵🇹

Santarém, Portugal

Fundação João Bento Raimundo

🇵🇹

Guarda, Portugal

Santa Casa da Misericórdia de Alcobaça

🇵🇹

Leiria, Portugal

Santa Casa da Misericórdia de Ponte de Lima

🇵🇹

Viana Do Castelo, Portugal

Inválidos do Comércio

🇵🇹

Lisboa, Portugal

Santa Casa da Misericórdia da Horta

🇵🇹

Açores, Portugal

© Copyright 2025. All Rights Reserved by MedPath